The German GBA has published today the details of the benefit assessment of drugs. It is quite a massive document and in German only for the time being. I will post a more in depth summary in English once I had time to digest it.
From 2011 onwards new medicines will have to undergo a benefit assessment. The GBA will commission this to IQWIG or other third parties. Prices can be freely set for the first six month, if no additional benefit can be demonstrated the drug will thereafter automatically be part of the therapeutic reference price system. If an additional therapeutic benefit is established manufacturers will negotiate prices with the statutory health insurance funds, if no agreement can be reached prices will be fixed by an independent arbitrary commission taking into consideration the EU price level.
http://www.g-ba.de/informationen/beschluesse/zum-aufgabenbereich/47/
Subscribe to:
Post Comments (Atom)
Blog Archive
-
►
2008
(75)
- January (14)
- February (7)
- March (10)
- April (6)
- May (4)
- June (3)
- July (7)
- August (3)
- September (4)
- October (9)
- November (5)
- December (3)
-
►
2009
(41)
- January (8)
- February (4)
- March (4)
- April (4)
- May (1)
- June (5)
- July (2)
- August (3)
- September (3)
- October (2)
- November (2)
- December (3)
-
►
2010
(31)
- January (1)
- February (8)
- March (2)
- May (2)
- June (2)
- July (3)
- August (2)
- September (4)
- October (3)
- November (2)
- December (2)
-
▼
2011
(29)
- January (6)
- February (3)
- March (1)
- May (2)
- June (4)
- July (3)
- August (2)
- September (4)
- October (3)
- November (1)
-
►
2012
(16)
- January (1)
- February (4)
- May (3)
- July (2)
- August (1)
- October (1)
- November (1)
- December (3)
1 comment:
I suspect you will enjoy reading my attempts to note trends and reform the industry, at www.pharma-insights.biz/.
I was at Pfizer, World Headquarters, for 13 years, and been consulting the past two years.
Kind regards, Larry
Post a Comment